A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Latest Information Update: 17 Aug 2023
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Primary endpoint has been met. (Overall Survival(OS)) , according to Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results (cutoff date of date: 18 Nov 2021) of an analysis based on 228 deaths presented at the 47th European Society for Medical Oncology Congress